Reading HSTM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HSTM free→Reading HSTM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HSTM free→
NASDAQHealth CareHealth Information ServicesSnapshot 2026-06-12
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and earnings quality is robust, cash backs up reported profits. Management's recent track record has been fairly steady, while risk is elevated and the sector backdrop is a headwind. Compared with sector peers, HSTM is above typical. Peer multiples imply a price about 23% below where it trades (it looks expensive on this basis); the read is fair, quality intact. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 6 valuation methods, at three horizons. Current price $26.13. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $26 the market pays 34× p/e — above the 14× p/e peer median but in line with its own 50× history. That premium reflects a durable franchise our peer-anchored $20 fair value understates; treat the 'expensive vs peers' read with low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 31% near-term growth, ahead of our forecast of about 7%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 3.18x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.18 → $0.18 (+0.0% / 30d). 0 raised, 0 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d. 40% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$137.
How much price usually moves either way.
On a bad day, this stock has moved -$262.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,206.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: A successful buyback shows that management believes in the company's value. It can help the stock price.
Confirms:The company repurchases shares totaling at least $5 million by the end of Q2 2026.
Disproves:No significant share repurchases occur by the end of Q2 2026.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for HSTM yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 4, 2026, HealthStream, Inc. (the “Company”) issued a press release announcing results of operations for the first quarter ended March 31, 2026 and reaffirming guidance for the full year 2026, the text of which is set forth in Exhibit 99.1.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks more expensive than peers.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Technology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
HSTM HealthStream, Inc. | Above typical Show detailsSector percentile: 97 of 100 | full | elevated |
VEEV Veeva Systems | Above typical Show detailsSector percentile: 77 of 100 | full | elevated |
SOLV Solventum | Typical Show detailsSector percentile: 68 of 100 | fair | moderate |
TEM TEMPUS AI, INC. | Above typical Show detailsSector percentile: 70 of 100 | — | elevated |
TXG 10X Genomics, Inc. | Typical Show detailsSector percentile: 44 of 100 | expensive | elevated |
2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The company continues to reaffirm its full-year 2026 guidance for revenue, net income, and adjusted EBITDA.
The company has increased its quarterly dividend to $0.035 per share.
The company has authorized a share repurchase program to repurchase up to $10.0 million of outstanding shares.
Why it matters: The earnings report will show how well the company is meeting its full-year guidance after a recent miss.
Confirms one read:Q2 earnings meet or exceed the full-year guidance reaffirmed in May 2026.
Confirms the other:Q2 earnings miss again, raising doubts about the full-year guidance.
Why it matters: A higher dividend shows the company is strong. It also shows they want to give value to shareholders.
Confirms:The company will announce a dividend increase above the current $0.035 per share.
Disproves:The company maintains the current dividend of $0.035 per share without increase.
Why it matters: A drop in revenue growth below its median could signal challenges in the growth phase.
Confirms:Revenue growth drops below the median growth rate for the sector.
Disproves:If revenue growth is steady or goes up, it supports the growth story.
Why it matters: If revenue growth drops below 10%, it may signal a slowdown in demand. This could impact future guidance and investor confidence.
Confirms:Q2 revenue growth prints below 10% year over year.
Disproves:Q2 revenue growth stays at or above 10% year over year.
Chief Operating Officer and Executive Vice President — Michael M. Collier: Michael M. Collier was promoted to Chief Operating Officer and Executive Vice President.
Other Events. On May 4, 2026, we announced that our Board of Directors declared a quarterly cash dividend under the Company's dividend policy in the amount of $0.035 per share of the Company’s outstanding common stock, which dividend will be payable on May 29, 2026 to holders of record on May 18, 2026.